Final 5-year outcomes from the endeavor zotarolimus-eluting stent clinical trial program: Comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents

JACC: Cardiovascular Interventions

Volumn 6, Issue 5, 2013, Pages 504-512

  Kandzari, David E ^a   Leon, Martin B ^b   Meredith, Ian ^c   Fajadet, Jean ^d   Wijns, William ^e   Mauri, Laura ^f  

^a PIEDMONT HEART INSTITUTE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MONASH UNIVERSITY   (Australia)

^d CLINIQUE PASTEUR   (France)

^e CARDIOVASCULAR CENTER   (Belgium)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

drug eluting stent; percutaneous coronary intervention; stent thrombosis; zotarolimus

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; BARE METAL STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS;

AGED; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877973184     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.12.125     Document Type: Article

References (42)

1. M.C. Morice, P.W. Serruys, J.E. Sousa A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. M.C. Morice, A. Colombo, B. Meier Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial JAMA 295 2006 895 904
3. D.E. Kandzari, M.B. Leon, J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447
4. L. Mauri, E.J. Orav, S.C. Candia, D.E. Cutlip, R.E. Kuntz Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials Circulation 112 2005 2833 2839
5. S.G. Ellis, J.J. Popma, J.M. Lasala Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial J Am Coll Cardiol 45 2005 1193 2000
6. S.J. Pocock, A.J. Lansky, R. Mehran Angiographic surrogate endpoints in drug-eluting stent trials: a systematic evaluation based on individual patient data from eleven randomized controlled trials J Am Coll Cardiol 51 2008 23 32
7. Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006 http://www.fda.gov/ohrms/dockets/ac/ cdrh06.html#circulatory Accessed August 25, 2012
8. M.B. Leon, E. Nikolsky, D.E. Cutlip Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial J Am Coll Cardiol Intv 3 2010 1043 1050
9. P.C. Smits, E. Kedhi, K.J. Royaards 2-Year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice COMPARE (comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
10. G.G. Stefanini, B. Kalesan, P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial Lancet 378 2011 1940 1948
11. I.T. Meredith, J. Ormiston, R. Whitbourn First-in-human study of Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial EuroIntervention 1 2005 157 164
12. J. Fajadet, W. Wijns, G.J. Laarman ENDEAVOR II Investigators Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 114 2006 798 806
13. Food and Drug Administration Medtronic Briefing Index. Endeavor clinical experience - Individual trial summaries. 7. ENDEAVOR PK http://www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4322b1-01-medtronic-index.html Accessed April 1, 2013
14. H.P. Schultheiss, E. Grube, K.H. Kuck Endeavor II Continued Access Investigators Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry EuroIntervention 3 2007 76 81
15. M.B. Leon, L. Mauri, J.J. Popma ENDEAVOR IV Investigators A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
16. D.E. Cutlip, S. Windecker, R. Mehran Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
17. S. Cook, E. Ladich, G. Nakazawa Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
18. G. Guagliumi, V. Sirbu, G. Musumeci Examination of the in vivo mechanisms of late drug-eluting stent thrombosis J Am Coll Cardiol Intv 5 2012 12 20
19. G. Nakazawa, F. Otsuka, M. Nakano The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
20. R. Virmani, G. Guagliumi, A. Farb Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705
21. G. Nakazawa, A.V. Finn, M. Vorpahl, E.R. Ladich, F.D. Kolodgie, R. Virmani Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents J Am Coll Cardiol 57 2011 390 398
22. T.F. Lüscher, J. Steffel, F.R. Eberli Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058
23. A.V. Finn, G. Nakazawa, M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
24. M. Joner, A.V. Finn, A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
25. G. Guagliumi, G. Musumeci, V. Sirbu ODESSA Trial Investigators Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents J Am Coll Cardiol Intv 3 2010 531 539
26. J.S. Kim, I.K. Jang, C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial J Am Coll Cardiol Intv 2 2009 1240 1247
27. M. Hamilos, J. Sarma, M. Ostojic Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses Circ Cardiovasc Interv 1 2008 193 200
28. D.I. Shin, K.B. Seung, P.J. Kim Long-term coronary endothelial function after zotarolimus-eluting stent implantation A 9-month comparison between zotarolimus-eluting and sirolimus-eluting stents Int Heart J 49 2008 639 652
29. J.W. Kim, H.S. Seo, J.H. Park A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial function J Am Coll Cardiol 53 2009 1653 1659
30. L. Räber, L. Wohlwend, M. Wigger Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial Circulation 123 2011 2819 2828
31. C.A. Collet, J.R. Costa, A. Abizaid Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents J Am Coll Cardiol Intv 4 2011 1067 1074
32. R.A. Byrne, A. Kastrati, K. Tiroch Two-year clinical and angiographic outcomes from a randomized of polymer-free dual drug-eluting stents versus polymer-based cypher and Endeavor drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
33. D.E. Kandzari, L. Mauri, J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
34. B.E. Claessen, M.A. Beijk, V. Legrand Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
35. M.B. Leon, D.E. Kandzari, L. Mauri TCT-24 the "final" five-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent J Am Coll Cardiol 58 Suppl 2011 B8
36. D.S. Pinto, G.W. Stone, S.G. Ellis Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial J Am Coll Cardiol 48 2006 32 36
37. T. Uchida, J. Popma, G.W. Stone Clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "occlustenotic" reintervention in patients with intermediate lesions J Am Coll Cardiol Intv 3 2010 403 411
38. D.E. Kandzari, C.S. Barker, M.B. Leon, R. Mehran Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents J Am Coll Cardiol Intv 4 2011 1119 1128
39. K. Rasmussen, M. Maeng, A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (sort OUT III): a randomized controlled superiority trial Lancet 375 2010 1090 1099
40. M. Maeng, H.H. Tilsted, L. Okkels-Jensen Three-year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents J Am Coll Cardiol Intv 5 2012 812 818
41. D.W. Park, Y.H. Kim, S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
42. E. Camenzind, W. Wijns, L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomized multicentre open-label controlled trial Lancet 380 2012 1396 1405